Suggestions
Peter Nestorov
Founder & CEO at Scailyte | Precision medicine, omics & AI
Peter Nestorov is a prominent figure in the business and biotechnology sectors, currently serving as a Group Chair at CEO Collaborative Forum.12 Based in Basel, Switzerland, Nestorov brings a wealth of experience to his role, having previously held positions in other organizations.1
Professional Background
CEO of Scailyte: Nestorov is also the CEO and Co-Founder of Scailyte AG, a company that specializes in single-cell analytics.45 Under his leadership, Scailyte has grown to employ over 20 people and has made significant strides in the field of biotechnology.6
Contributions to Medical Research: In collaboration with the University of Bern, Nestorov and his team at Scailyte have recently made groundbreaking discoveries in the field of endometriosis research.3 This achievement highlights his commitment to advancing scientific knowledge and improving healthcare outcomes.
Role at CEO Collaborative Forum
As a Group Chair at CEO Collaborative Forum, Nestorov has been praised for his outstanding performance.2 He has been instrumental in fostering trust and enabling valuable experiences within the organization's Trust Group.2 His leadership style appears to be focused on collaboration and enabling others to reach their potential.
LinkedIn Presence
Peter Nestorov maintains an active presence on LinkedIn, where his username is indeed "peternestorov".2 He uses the platform to share insights, celebrate achievements, and engage with his professional network.
Peter Nestorov's multifaceted career, spanning leadership roles in both the CEO Collaborative Forum and Scailyte AG, demonstrates his expertise in business leadership and biotechnology innovation. His work continues to make significant impacts in these fields, particularly in the areas of single-cell analytics and medical research.
Highlights
Last week I was at the #BIO2024 exploring partnership opportunities with biotech & pharma companies from around the world. This was a very well organized, vibrant & colorful event in the emerging biotech hub San Diego. Some key insights:
- biomarker-driven drug discovery and companion diagnostics is gaining importance outside of oncology, in particular in auto-immunity;
- there is a new wave of immuno-oncology drugs, which are showing very promising results with overall response rates of >80% and complete response in >40% of patients in early clinical trials.
- genAI and large language models are a hype also in the biotech space - a lot of talk with no results or solid science to back up the claims of these new genAI companies - the bubble gets inflated.
We are looking for a US-based Head of BD to join us on the exciting journey of single-cell & AI-driven precision medicine! Please share & apply if you feel this is a fit for you!
